Skip to main content
SpringerLink
Log in

The efficacy of Alfuzosin treatment in patients with prostatism

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective: Alfuzosin, a quinazoline derivative, is a selective alpha-laadreneceptor antagonist with further selectivity for the alpha-1adrenoceptors of the lower urinary tract and lesser affinity for vascularalpha-1 adrenoceptors. The present study evaluates the efficacy ofalfuzosin in a group of the patients with prostatism.Methods: Eighty-two patients with lower urinary tract symptoms agedfrom 55 to 76 years (mean age 62.36±6.4) were enrolled in the study. Thepatients were evaluated by blood pressure measurement, digital rectalexamination, serum total and free prostate specific antigen (PSA)determinations by Tandem R-Assay with the reference range of 0.0 to 4.0ng/ml, international prostate symptom score (IPSS), volume measurementby transrectal prostate ultrasound, blood biochemistry, uroflowmetry,postvoiding residual urine (PVRU) assessment. The patients treated withalfuzosin 2.5 mg three times a day for 3 months were re-evaluated by bloodpressure measurement, IPSS, urine flow rate (UFR) and PVRU assessmentin the 2nd week and in the 6th week, and by blood pressuremeasurement, IPSS, blood biochemistry, serum total and free PSAdeterminations, UFR and PVRU assessment in the 3rd month. Statisticalanalysis was performed using student-t test, and p value was consideredsignificant when less than 0.05.Results: Although IPSS significantly decreased in the 2nd weekof the treatment compared to pre-treatment value, it reached a maximumdecrease in the 6th week of the treatment. There were statisticallysignificant difference between in the 2nd week IPSS value and the6th week IPSS value. However, no difference was seen between the6th week IPSS value and the 3rd month IPSS value.No significant difference was observed between pre-treatment values andthe 2nd week values regarding UFR and PVRU. Peak flow rate andPVRU significantly changed in the 6th week of the treatment and theyreached maximum change in the 3rd month. Difference was alsosignificant between the values in the 6th week of the treatment andthose in the 3rd month of the treatment.According to the blood biochemical analysis, total and free PSA levelsbefore and after the treatment, there were no significantly difference.Additionally, alfuzosin had no effect on blood pressure. Before, during andafter the treatment, blood pressure did not change significantly.Conclusion: Present study showed that symptomatic improvement withalfuzosin treatment began in the 2nd week, reaching the maximum levelin the 6th week whereas urodynamic parameters began to improve inthe 6th week and reached the maximum level in the 3rd month withno effect on blood pressure and blood biochemical test.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roehrborn CG. The assessment of medical treatment for benign prostatic hyperplasia. In Kurth K, Newling DWW, eds. Benign Prostatic Hyperplasia. New York: Wiley-Liss Inc, 1994, 175–190

    Google Scholar 

  2. Finasteride Study Group. Finasteride (MK–906) in treatment of benign prostatic hyperplasia. The Prostate 1993; 22: 291–299

    Google Scholar 

  3. Shapiro E, Hartano V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostatic smooth muscle. The Prostate 1992; 21: 297–307

    Google Scholar 

  4. Jardin A, Andersoon KE, Caine M et al. Alpha blockers therapy in benign prostatic hyperplasia. In Cockett ATK, Khoury S, Aso Y, Chetelain C, Denis L, Griffiths K, Murphy G, eds. The 3rd International Consultation on Benign Prostatic Hyperplaia. SCI, 1995, 529–571

  5. Andersson KE, Jardin A, Langer S, Roehrborn CG. Urose-lectivity. In Debruyne FMJ, Jardin A, Roehrborn CG, Langer S, eds. Benign Prostatic Hperplasia-the Place of Alfuzosin (from basic pharmacology to clinical practice). Synthelabo, 1998, 45–62

  6. Caine M, Raz S, Ziegler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 27: 193–202

    Google Scholar 

  7. Kirby R, Roehrborn CG, Debruyne FMJ. Management of benign prostatic hyperplasia. In Debruyne FMJ, Jardin A, Roehrborn CG, Langer S, eds. Benign Prostatic Hyperplasia-the Place of Alfuzosin (from basic pharmacology to clinical practice). Syntalebo, 1998, 27–44

  8. Jardin A, Bensadoun H, Delanche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–146

    Google Scholar 

  9. Buzelin JM, Roths S, Geffriaud-Ricouard C, Delauche-Cavaller MC. Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1991; 31: 190–119

    Google Scholar 

  10. Hansen BJ, Nordling J, Mensink HJA, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicenter double-blind placebo controlled trial. Scand J Urol Nephrol (Suppl) 1994; 157: 169–176

    Google Scholar 

  11. Schulman CC, De Sy W, Vandenderis M et al. Belgian multi-center clinical study of alfuzoisn, a selective alpha-1 blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin group. Acta Urol Belg 1994; 62: 15–21

    Google Scholar 

  12. The Italian Afluzosin Group. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patients’ quality of life. Eur Urol 1995; 27: 128–134

    Google Scholar 

  13. Kirby RS. Clinical uroselectivit6y of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol (Suppl-2) 1998; 33: 19–27

    Google Scholar 

  14. Djavan B, Marberger M. A mmeta-analysis of the efficacy and tolerability of alpha-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13

    Google Scholar 

  15. Jardin A. Alfuzosin. In Kirby R, McConnell JD, Fitzpatick JM, Roehrborn CG, Bryle P, eds.Textbook of Benign Prostatic Hyperplasia. Isis Medical Media, 1996, 295–307

  16. Jardin A, Bensadou H, Delauche-Cavallier MC, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12–18 month assessment. Br J Urol 1993; 72: 615–620

    Google Scholar 

  17. Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. Br J Urol 1994, 74: 579–584

    Google Scholar 

  18. Wilde MI, Fitton A, McTarish D. Alfuzosin: a review of its pharmacodynamic and pharmokinetic properties and thera-peutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 410–429

    Google Scholar 

  19. Lepor H, Shapiro E. Prostatic alpha adrenoceptors. In Kurth K, Newling NWW, eds. Benign Prostatic Hyperplasia. New York: Wiley-Liss Inc, 1994, 271–277

    Google Scholar 

  20. Scott MG, Deering AH, McMahon MT et al. Haemody-namic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. Eur Clin Pharmacol 1989; 37: 53–58

    Google Scholar 

  21. Teillac P, Delauche-Cavallier MC, Attali P, the DUALF Group. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58–64

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology Clinic, Ankara Numune Education and Research Hospital, Ankara, Turkey

    M. Murad Başar, Ali Atan, Osman Özergin & Müslüm Yıldız

Authors
  1. M. Murad Başar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Atan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osman Özergin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Müslüm Yıldız
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murad Başar, M., Atan, A., Özergin, O. et al. The efficacy of Alfuzosin treatment in patients with prostatism. Int Urol Nephrol 33, 493–497 (2001). https://doi.org/10.1023/A:1019555020671

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1019555020671

Search

Navigation